0.68%
0.59%
-5.61%
-14.14%
-18.67%
21.44%
19.97%
AI Spotlight on MRK
Company Description
Merck & Co., Inc.operates as a healthcare company worldwide.It operates through two segments, Pharmaceutical and Animal Health.
The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers.
The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc.to jointly develop and commercialize long-acting treatments in HIV.Merck & Co., Inc.
was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Market Data
| Last Price | 98.95 |
| Change Percentage | 0.68% |
| Open | 99.41 |
| Previous Close | 98.28 |
| Market Cap ( Millions) | 250308 |
| Volume | 8277529 |
| Year High | 134.63 |
| Year Low | 94.48 |
| M A 50 | 99.55 |
| M A 200 | 114.69 |
Financial Ratios
| FCF Yield | 5.93% |
| Dividend Yield | 3.15% |
| ROE | 29.27% |
| Debt / Equity | 85.68% |
| Net Debt / EBIDTA | 122.78% |
| Price To Book | 5.63 |
| Price Earnings Ratio | 20.62 |
| Price To FCF | 16.87 |
| Price To sales | 3.96 |
| EV / EBITDA | 14.28 |
News
- Jan -30 - Merck to stop lung condition drug study early due to strong efficacy data
- Jan -30 - Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
- Jan -29 - The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings
- Jan -29 - Diatech Pharmacogenetics Expands Collaboration with Merck to Enhance Patient Access to Personalized Medicine in the Middle East and Africa
- Jan -28 - Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase Authorization
- Jan -28 - MRK's sNDA for Welireg in Rare Tumors Gets FDA's Priority Tag
- Jan -28 - Merck Q4 Earnings Coming Up: Buy, Hold or Sell MRK Stock Now?
- Jan -27 - MRK Reports Mixed Keytruda Combo Study Data in Gastroesophageal Cancer
- Jan -27 - Why This Beaten-Down Stock Is a Buy in 2025 and Beyond
- Jan -27 - FDA Grants Priority Review to Merck's Application for WELIREG® (belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (PPGL)
- Jan -25 - These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024
- Jan -24 - Merck and Eisai's cancer drugs fail to improve overall survival in late-stage trial
- Jan -24 - Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma
- Jan -23 - 4 Mega-Cap High-Yield Dividend Giants Look Like Huge 2025 Winners
- Jan -22 - Kennedy would keep legal fees from Merck cases if confirmed
- Jan -21 - Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know
- Jan -21 - Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?
- Jan -20 - Merck: 3x Pipeline And Undervaluation Make It A Buy
- Jan -20 - High-Quality Dividend Growth Stocks Near 52-Week Lows: Merck Is Magnificent
- Jan -19 - Despite Setbacks, Moderna Sees Opportunity In Avian Flu, Merck Partnership
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Pharmaceutical
Expected Growth : 6 %
What the company do ?
Merck & Co., Inc. is a multinational pharmaceutical company that develops, manufactures, and markets various prescription medicines, vaccines, and animal health products.
Why we expect these perspectives ?
Merck & Co., Inc.'s pharmaceutical segment growth is driven by strong demand for its key products, including Keytruda, Gardasil, and Bridion. Increasing adoption of immunotherapies, growing prevalence of chronic diseases, and strategic M&A activities also contribute to growth. Additionally, investments in R&D and expansion into emerging markets further support the segment's 6% growth rate.
Segment n°2 -> Animal Health
Expected Growth : 4 %
What the company do ?
Animal Health from Merck & Co., Inc. provides veterinary pharmaceuticals and services to improve animal health and well-being.
Why we expect these perspectives ?
Merck's Animal Health segment growth is driven by increasing demand for livestock vaccines and parasiticides, expansion into emerging markets, and strategic acquisitions. Additionally, the rising need for animal protein, growing pet ownership, and advancements in veterinary care are contributing to the segment's 4% growth.
Segment n°3 -> Other
Expected Growth : 3 %
What the company do ?
The 'Other' segment from Merck & Co., Inc. includes revenues from the company's remaining businesses, such as consumer care and animal health.
Why we expect these perspectives ?
Merck's 'Other' segment, with 3% growth, is driven by increasing demand for its consumer care products, such as Claritin and Coppertone, as well as growth in its Allergen immunotherapy business. Additionally, the company's alliance with AstraZeneca to market Nexium and the expansion of its biosimilar portfolio contribute to this growth.
Merck & Co., Inc. Products
| Product Range | What is it ? |
|---|---|
| Gardasil | Human Papillomavirus (HPV) vaccine to prevent cervical, vulvar, and vaginal cancers and genital warts |
| Keytruda | Anti-PD-1 therapy for the treatment of various types of cancer, including melanoma, lung cancer, and kidney cancer |
| Januvia | DPP-4 inhibitor for the treatment of type 2 diabetes |
| Isentress | Integrase inhibitor for the treatment of HIV-1 infection |
| Zepatier | Direct-acting antiviral for the treatment of chronic hepatitis C |
| Bridion | Neuromuscular blocking agent reversal agent |
| Noxafil | Antifungal medication for the treatment of invasive aspergillosis and mucormycosis |
Merck & Co., Inc.'s Porter Forces
Threat Of Substitutes
Merck & Co., Inc. faces moderate threat from substitutes due to the presence of alternative treatments and generic drugs in the market.
Bargaining Power Of Customers
Merck & Co., Inc. has a diverse customer base, which reduces the bargaining power of individual customers, making it a low threat.
Bargaining Power Of Suppliers
Merck & Co., Inc. relies on a network of suppliers for raw materials and services, but has some bargaining power due to its large scale of operations.
Threat Of New Entrants
The pharmaceutical industry has high barriers to entry, including significant R&D investments and regulatory hurdles, making it a low threat for Merck & Co., Inc.
Intensity Of Rivalry
The pharmaceutical industry is highly competitive, with many established players, making the intensity of rivalry a high threat for Merck & Co., Inc.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 48.46% |
| Debt Cost | 5.95% |
| Equity Weight | 51.54% |
| Equity Cost | 5.95% |
| WACC | 5.95% |
| Leverage | 94.04% |
Merck & Co., Inc. : Quality Control
Merck & Co., Inc. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| LLY | Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, … |
| GILD | Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, … |
| BMY | Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, … |
| AMGN | Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat … |
| JNJ | Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Bristol-Myers Squibb
A-Score
1-Year Total Return ->
🥈
Gilead Sciences
A-Score
1-Year Total Return ->
🥉
Merck
A-Score
1-Year Total Return ->
4
J&J
A-Score
1-Year Total Return ->
5
Lilly
A-Score
1-Year Total Return ->
6
